STOCK TITAN

Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Iridex (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has scheduled its second quarter 2025 financial results release for August 12, 2025 after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 using passcode 2197032, or access the webcast through Iridex's investor relations website.

Iridex (Nasdaq: IRIX), fornitore di sistemi medici laser per il trattamento del glaucoma e delle malattie retiniche, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025 dopo la chiusura del mercato.

La società terrà una conference call alle 14:00 PT / 17:00 ET dello stesso giorno. Gli investitori potranno partecipare telefonicamente chiamando il numero +1-888-596-4144 con il codice di accesso 2197032, oppure seguire la diretta web tramite il sito web delle relazioni con gli investitori di Iridex.

Iridex (Nasdaq: IRIX), proveedor de sistemas médicos basados en láser para glaucoma y enfermedades retinianas, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025 después del cierre del mercado.

La compañía realizará una llamada conferencia a las 2:00 p.m. PT / 5:00 p.m. ET el mismo día. Los inversores pueden unirse por teléfono marcando +1-888-596-4144 con el código 2197032, o acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de Iridex.

Iridex (나스닥: IRIX)는 녹내장 및 망막 질환을 위한 레이저 기반 의료 시스템 제공업체로, 2025년 2분기 재무 결과2025년 8월 12일 장 마감 후에 발표할 예정입니다.

회사는 같은 날 오후 2시 PT / 오후 5시 ET에 컨퍼런스 콜을 진행합니다. 투자자들은 전화번호 +1-888-596-4144에 접속 코드 2197032를 입력하여 참여하거나 Iridex 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있습니다.

Iridex (Nasdaq : IRIX), fournisseur de systèmes médicaux laser pour le glaucome et les maladies rétiniennes, a prévu la publication de ses résultats financiers du deuxième trimestre 2025 pour le 12 août 2025 après la clôture du marché.

La société tiendra une conférence téléphonique à 14h00 PT / 17h00 ET le même jour. Les investisseurs peuvent participer par téléphone au +1-888-596-4144 avec le code d'accès 2197032, ou accéder au webcast via le site des relations investisseurs d'Iridex.

Iridex (Nasdaq: IRIX), ein Anbieter von laserbasierten Medizinsystemen für Glaukom und Netzhauterkrankungen, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 12. August 2025 nach Börsenschluss angekündigt.

Das Unternehmen wird am selben Tag um 14:00 Uhr PT / 17:00 Uhr ET eine Telefonkonferenz abhalten. Investoren können telefonisch unter +1-888-596-4144 mit dem Zugangscode 2197032 teilnehmen oder den Webcast über die Investor-Relations-Website von Iridex verfolgen.

Positive
  • None.
Negative
  • None.

MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025.

The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing passcode: 2197032 followed by pressing #. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com

MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions.  © 2025 Iridex Corporation.  All rights reserved.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com


FAQ

When will Iridex (IRIX) report Q2 2025 earnings?

Iridex will release its Q2 2025 financial results on Tuesday, August 12, 2025 after the market closes.

How can investors access Iridex's Q2 2025 earnings call?

Investors can join the call at 2:00 p.m. PT / 5:00 p.m. ET by dialing +1-888-596-4144 (passcode: 2197032) or watch the webcast on Iridex's investor relations website.

What time is Iridex's (IRIX) Q2 2025 earnings conference call?

The earnings conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET on August 12, 2025.

What does Iridex Corporation (IRIX) do?

Iridex is a worldwide leader in laser-based medical systems, delivery devices, and procedure probes for treating glaucoma and retinal diseases.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

21.49M
12.06M
27.9%
18.63%
1.8%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW